Abstract:Background: Mesenchymal stromal cells (MSCs) have broad potential as a cell therapy including for the treatment of drug-resistant inflammatory conditions with abnormal T cell proliferation such as graft-versus-host disease (GVHD). Clinical success, however, has been complicated by the heterogeneity of culture-expanded MSCs as well as donor variability. Here, we devise culture conditions that promote expansion of MSCs with enhanced immunomodulatory functions both in vitro and in animal models of GVHD. Methods: Human bone marrow-derived MSCs were expanded at high-confluency (MSCHC) and low-confluency state (MSCLC). Their immunomodulatory properties were evaluated with in vitro co-culture assays based on suppression of activated T cell proliferation and secretion of pro-inflammatory cytokines from activated T cells. Metabolic state of these cells was determined, while RNA sequencing was performed to explore transcriptome of these MSCs. Ex vivo expanded MSCHC or MSCLC was injected into human peripheral blood mononuclear cells (PBMC)-induced GVHD mouse model to determine their in vivo therapeutic efficacy based on clinical grade scoring, human CD45+ blood count and histopathological examination. Results: As compared to MSCLC, MSCHC significantly reduced both the proliferation of anti-CD3/CD28-activated T cells and secretion of pro-inflammatory cytokines upon MSCHC co-culture across several donors even in the absence of cytokine priming. Mechanistically, metabolic analysis of MSCHC prior to co-culture with activated T cells showed increased glycolytic metabolism and lactate secretion compared to MSCLC, consistent with their ability to inhibit T cell proliferation. Transcriptome analysis further revealed differential expression of immunomodulatory genes including TRIM29, BPIFB4, MMP3 and SPP1 in MSCHC as well as enriched pathways including cytokine-cytokine receptor interactions, cell adhesion and PI3K-AKT signalling. Lastly, we demonstrate in a human PBMC-induced GVHD mouse model that delivery of MSCHC showed greater suppression of inflammation and improved outcomes compared to MSCLC and saline controls. Conclusion: Our study provides evidence that ex vivo expansion of MSCs at high confluency alters the metabolic and transcriptomic states of these cells. Importantly, this approach maximizes the production of MSCs with enhanced immunomodulatory functions without priming, thus providing a non-invasive and generalizable strategy for improving the use of MSCs for the treatment of inflammatory diseases.

Cross Talk Between Glucose Metabolism and Immunosuppression in IFN-γ–primed Mesenchymal Stem Cells

Commitment to Aerobic Glycolysis Sustains Immunosuppression of Human Mesenchymal Stem Cells.

Immunomodulatory properties of mesenchymal stromal/stem cells: The link with metabolism

Leptin Enhances Glycolysis Via OPA1-mediated Mitochondrial Fusion to Promote Mesenchymal Stem Cell Survival.

The ATP synthase inhibition induces an AMPK-dependent glycolytic switch of mesenchymal stem cells that enhances their immunotherapeutic potential

Key Metabolic Pathways in MSC-Mediated Immunomodulation: Implications for the Prophylaxis and Treatment of Graft Versus Host Disease

Enhanced Immunosuppression of T Cells by Sustained Presentation of Bioactive Interferon-γ Within Three-Dimensional Mesenchymal Stem Cell Constructs

IFNβ enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism

Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair

HIF1α-dependent metabolic reprogramming governs mesenchymal stem/stromal cell immunoregulatory functions

Metabolic reprogramming of myeloid-derived suppressor cells in the context of organ transplantation

Expansion of human bone marrow-derived mesenchymal stromal cells with enhanced immunomodulatory properties

NAD+ salvage governs the immunosuppressive capacity of mesenchymal stem cells

Integrated Analysis of Transcriptome and Secretome From Umbilical Cord Mesenchymal Stromal Cells Reveal New Mechanisms for the Modulation of Inflammation and Immune Activation

A Critical Role of IFNγ in Priming MSC-mediated Suppression of T Cell Proliferation Through Up-Regulation of B7-H1

WTAP/YTHDF1-mediated m6A modification amplifies IFN-γ-induced immunosuppressive properties of human MSCs

Priming mesenchymal stem/stromal cells with a combination of a low dose of IFN-γ and bortezomib results in potent suppression of pathogenic Th17 immunity through the IDO1-AHR axis.

Immunomodulatory Mechanisms of Mesenchymal Stem Cells and Their Potential Clinical Applications

Deconstructing transcriptional variations and their effects on immunomodulatory function among human mesenchymal stromal cells

Mesenchymal Stem Cells Ameliorate Mitochondrial Dysfunction in α - cells and Hyperglucagonemia in type 2 Diabetes via SIRT1/FoxO3a Signaling

Proteomic analysis and functional validation reveal distinct therapeutic capabilities related to priming of mesenchymal stromal/stem cells with IFN-γ and hypoxia: potential implications for their clinical use